US4005191A - Topical ointment composition - Google Patents
Topical ointment composition Download PDFInfo
- Publication number
- US4005191A US4005191A US05/628,972 US62897275A US4005191A US 4005191 A US4005191 A US 4005191A US 62897275 A US62897275 A US 62897275A US 4005191 A US4005191 A US 4005191A
- Authority
- US
- United States
- Prior art keywords
- composition
- mixture
- topical
- weight percent
- ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 109
- 229940100615 topical ointment Drugs 0.000 title claims abstract description 38
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 45
- 239000002674 ointment Substances 0.000 claims abstract description 30
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 26
- 239000012876 carrier material Substances 0.000 claims abstract description 26
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 22
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 22
- 229940031955 anhydrous lanolin Drugs 0.000 claims abstract description 21
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 21
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 21
- 239000008311 hydrophilic ointment Substances 0.000 claims abstract description 20
- 230000000699 topical effect Effects 0.000 claims abstract description 15
- 230000009885 systemic effect Effects 0.000 claims abstract description 13
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 claims description 9
- 229940045574 dibucaine hydrochloride Drugs 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 abstract description 16
- 230000006378 damage Effects 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 208000004210 Pressure Ulcer Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 208000028990 Skin injury Diseases 0.000 abstract 1
- 208000000558 Varicose Ulcer Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 239000004264 Petrolatum Substances 0.000 description 17
- 229940066842 petrolatum Drugs 0.000 description 17
- 235000019271 petrolatum Nutrition 0.000 description 17
- 210000002615 epidermis Anatomy 0.000 description 15
- 235000012254 magnesium hydroxide Nutrition 0.000 description 15
- 208000025865 Ulcer Diseases 0.000 description 12
- 229960001747 cinchocaine Drugs 0.000 description 11
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 11
- 230000035876 healing Effects 0.000 description 11
- 208000014674 injury Diseases 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 210000000416 exudates and transudate Anatomy 0.000 description 6
- 235000019388 lanolin Nutrition 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 239000004166 Lanolin Substances 0.000 description 5
- 230000001458 anti-acid effect Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229940039717 lanolin Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 229940069428 antacid Drugs 0.000 description 4
- 239000003159 antacid agent Substances 0.000 description 4
- 229940085868 calcium carbonate 250 mg Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 229940080947 magnesium hydroxide 200 mg Drugs 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 4
- 229960001907 nitrofurazone Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 3
- 206010011985 Decubitus ulcer Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000034693 Laceration Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000009519 contusion Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 108010016297 plasmin drug combination deoxyribonuclease Proteins 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006802 Burns second degree Diseases 0.000 description 2
- 206010006803 Burns third degree Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 208000003105 Diaper Rash Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- QSDSSSQWVNLFIG-UHFFFAOYSA-N Neosporin Natural products CC(O)CC1=C(OC)C(=O)C2=CC(O)=C3OCOC4=C(O)C=C5C6=C4C3=C2C1=C6C(CC(C)O)=C(OC)C5=O QSDSSSQWVNLFIG-UHFFFAOYSA-N 0.000 description 2
- 108010077913 Triamcinolone Acetonide Drug Combination Nystatin Neomycin Sulfate Gramicidin Proteins 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229940109357 desoxyribonuclease Drugs 0.000 description 2
- 108010046161 drug combination polymyxin B neomycin sulfate bacitracin zinc Proteins 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 229940001501 fibrinolysin Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960001048 fluorometholone Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- 210000003284 horn Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940053050 neomycin sulfate Drugs 0.000 description 2
- 229940049337 neosporin Drugs 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- -1 or to electrical Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940100611 topical cream Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010049047 Chapped lips Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- RREGISFBPQOLTM-UHFFFAOYSA-N alumane;trihydrate Chemical compound O.O.O.[AlH3] RREGISFBPQOLTM-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940111111 fibrinolysin and desoxyribonuclease Drugs 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910001679 gibbsite Inorganic materials 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 229940019974 pramoxine hydrochloride Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036409 touch and pain Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
Definitions
- This invention relates to the direct treatment of injured mammalian tissue, for example, abraded, lacerated or ulcerated tissues, through the use of a topical ointment composition which has the capacity of adjusting the acid-base balance of the area to which the composition is applied to a point where healing from within can take place.
- the skin, supporting body tissues, connective tissues and viscera are subject to a variety of irritations, infections and injuries. These often result in the disruption of the continuity, configuration and appearance of normal tissues and may appear as areas of ulceration, necrosis, contusion, laceration, inflammation and tumefaction.
- Conventional compositions for dressings to be applied to such irritated or injured tissues often act as foreign bodies and are frequently themselves a source of irritation which may impede the healing process and promote infection.
- the skin is composed of two layers, i.e., the epidermis or cuticle and the dermis or true skin.
- the epidermis is a thin outer layer composed of stratified epithelium.
- the epidermis being generally devoid of blood vessels, is dependent for its nutrition upon the vessels found in the dermis. These vessels end as capilliary loops in the papillae of the dermis.
- Keratinization results in the death of the cells. Keratin is the most insoluble of all proteinaceous material which gives the upper layer of the skin (the stratum corneum) a horn like consistency. During the life process, the outermost dead scales of keratin are gradually shed and replaced by more recently keratinized cells. Keratin also is found in the appendages of the skin, that is, in the nails and hair. In the lower animals it is found in the horns, hoofs and claws. In the palms of the hands and soles of the feet, the epidermis is much thicker than elsewhere.
- the true skin, corium or dermis lies just below the Malpighian layer and is formed of loose connective tissue which sends little elevations known as papillae into the cuticle or epidermis. At its deepest portions the dermis gradually passes into the areolar subcutaneous tissue. In the dermis, or more especially, in the subcutaneous tissue, a variable amount of adipose tissue exists. While the epidermis is not supplied with blood vessels, the dermis is very vascular and the sebaceous (oil) and sudoriferous (sweat) glands are located in the dermis. The oil glands, which reside in the deeper parts of the skin, are distributed in all areas of the body except the soles of the feet and the palms of the hands.
- the sebaceous secretion contains fats, proteins, water, salt, and remnants of epithelial cells.
- the sebum protects the structures of the skin and the hair against intolerable drying and breakage by oiling the same and thus the physical integrity of the skin is preserved. Additionally, the sebum prevents excessive loss of water by the skin.
- the epidermis of the skin which is composed of hard, resistant cells, forms the bodies first line of defense against mechanical and chemical injuries and, above all, against bacterial invasion, because the unbroken skin is substantially germ proof. This protection is evidenced by the frequent infections which occur when the skin is injured so as to expose the underlying tissues.
- the skin not only serves as a mechanical barrier but that it also possesses immunizing powers.
- the sense organs for heat and cold, touch and pain are located in the dermis.
- the skin helps to regulate body temperature through vasomotor reactions of blood vessels and through evaporation of perspiration. Perspiration sometimes has acidic and sometimes basic properties and its odor may be very marked and differs in various regions of the body.
- the skin also plays an important part in water metabolism, calcium metabolism and to a lesser degree, excretion and adsorption.
- Various injuries which effect the skin include those caused by allergic reactions, mechanical impact or abrasion, chemical attack, heat, etc. These may result in disruption of normal tissue continuity, configuration and appearance and may appear as areas of ulceration, necrosis, contusion, laceration, inflammation and tumefaction.
- Ulcer is a local defect or excavation of the surfaces of an organ produced by sloughing of necrotic inflammatory tissue
- Decubitus ulcer is an ulceration caused by prolonged pressure on a body area in a patient confined to bed;
- Necrosis is the death of a cell as a result of a disease or injury
- Contusion is an injury to tissues without breakage of the skin
- Laceration -- is a wound produced by tearing
- Inflammation is a specific tissue response to injury by living agents, or to electrical, chemical or mechanical trauma, evidenced by vascular dilatation, fluid exudation, or accumulation of lukocytes or any combination of the three;
- Tumefaction is a swelling or puffiness
- Rash -- is a temporary erruption on the skin
- Diaper Rash -- is a dermatitis of the gluteal region of infants.
- Erythema is a congestive or exudative redness of the skin caused by hyperima which is an excess of blood in a particular part;
- Edema is an abnormal accumulation of fluid in the intracellular spaces of the body
- Eczema is generally a skin disease having associated therewith, itching and redness.
- compositions useful for treatment of injuries to the skin are known in the prior art.
- compositions are the following:
- Furacin (a registered trademark of Eaton Laboratory, Norwich, New York) is a topical cream containing nitrofurazone in a base consisting of glycerine, cetyl alcohol, mineral oil, an ethoxylated fatty alcohol, methylparaben, propylparaben and water.
- the water miscible base is self-emulsifying in various body fluids.
- the topical cream finds use in the treatment or prophylaxis of the surface bacterial infections.
- Elase Ointment (a registered trademark of the Parke-Davis Company, Detroit, Michigan) is a combination of two lytic enzymes, fibrinolysin and desoxyribonuclease, in an ointment.
- the fibrinolysin component is derived from bovine plasma and the desoxyribonuclease is isolated in a purified form from bovine pancreas.
- the combination of these two enzymes is based on the observation that purulent exudates consist largely of fibrinous material and nucleoprotein.
- Desoxyribonuclease attacks the desoxyribonucleic acid (DNA) and fibrinolysin attacks principally fibrin of blood clots and fibrinous exudates.
- Elase is used topically as a debriding agent in a variety of inflammatory and infected lesions including (1) general surgical wounds, (2) ulcerative lesions, i.e., trophic, decubitus, stasis, arteriosclerotic; and (3) second and third degree burns.
- Oxylone (a registered trademark of the Upjohn Company, Kalamazoo, Michigan) contains fluorometholone, which is a steroid, in addition to glyceryl monostearate, spermaceti, polyethylene glycol emulsifier, water and preservatives.
- This material includes a water soluble vanishing cream base designed for use on exposed regions of the skin such as the face and hands and is allegedly effective because of the anti-inflammatory, anti-pruritic and vasoconstrictive action provided by the steroid, fluorometholone.
- the cream is used to obtain symptomatic relief and adjunctive management of various dermatoses including sunburn, eczema and diaper rash.
- Mycolog (a registered trademark of E. R. Squibb & Sons, Princeton, New Jersey) is a dermatologic preparation used in cases of dermatitis complicated with a superficial bacterial infection. Among other things, it is anti-fungal and anti-bacterial and contains nystatin, neomycin sulfate, gramicidin, and triamcinolone acetonide either in a vanishing cream base or in a protective base of polyethylene and mineral oil gel.
- Neosporin (a registered trademark of the Burroughs-Wellcome Company, North Carolina) provides anti-bacterial action against commonly occuring bacteria known to be topical invaders.
- the ointment contains neomycin sulfate, zinc bacitracin and polymyxin B-sulfate.
- compositions even though many of the same include fungicides, bacteriacides or hazardous steroids, still do not provide either the degree or speed of healing which is obtained with the composition of the instant invention in the treatment of many injuries to the skin, as will be clearly shown in the examples infra.
- the composition of the instant invention is useful in treating various injuries to the skin which result in ulcerated, lacerated or abraded tissue and in particular the composition is useful in the treatment of decubitus ulcers.
- the composition is in the form of a topical ointment and contains a mixture of non-systemic bases, a lanolin base carrier material and a hydrophilic ointment carrier material.
- the mixture of bases is present in the composition in an amount effective to adjust the acid-base balance of the area of topical application to a point which corresponds with normal, healthy body tissue.
- the topical ointment may also include a compound having anesthetic properties.
- the mixture of non-systemic bases consists essentially of from about 7 to about 82 weight percent calcium carbonate, from about 5 to about 77 weight percent magnesium hydroxide and from about 6 to about 80 weight percent aluminum hydroxide and the percentages of these enumerated bases total approximately 100 percent of the mixture thereof.
- the weight ratio of the anhydrous lanolin base carrier material to the hydrophilic ointment base carrier material in the composition ranges from approximately 2:1 to approximately 1:2.
- the weight ratio of base carrier materials to non-systemic bases in said composition should be in the range of about 21:1 to 213:1 to achieve the best results.
- the compound having anesthetic properties may be, for example, dibucaine, benzocaine, lidocaine, pramoxine hydrochloride, etc. However, dibucaine is preferred.
- the instant invention provides a method for preparing such a topical ointment composition which comprises forming a paste comprising a mixture of non-systemic bases including calcium carbonate, magnesium hydroxide and aluminum hydroxide and a sufficient amount of water to provide a smooth, moist paste and separately admixing an anhydrous lanolin base carrier material and a hydrophilic ointment base carrier material in a weight ratio ranging from approximately 2:1 to approximately 1:2. Thereafter the admixture of base carrier materials is blended with the paste to obtain a workable homogeneous paste.
- a mixture of non-systemic bases consisting essentially of about 7 to about 82 weight percent calcium carbonate, from about 5 to about 77 weight percent magnesium hydroxide and from about 6 to about 80 weight percent aluminum hydroxide is provided.
- the percentages of the components in the mixture total approximately 100 percent thereof and a sufficient amount of water is added to the mixture to provide a smooth, moist paste which preferably has a pH in the range of from about 8.0 to about 9.5.
- An anhydrous lanolin base carrier material and a hydrophilic ointment base carrier material are admixed in a weight ratio ranging from approximately 2:1 to approximately 1:2 and the mixture of bases is blended with the admixture of base carrier materials.
- the blended composition contains an amount of the basic paste effective to essentially adjust the acid-base balance at the area of topical application to a point which corresponds with normal, healthy body tissue and in this connection, the weight ratio of base carrier materials to nonsystemic bases in said composition should preferably be in the range of from about 21:1 to about 213:1.
- the admixture of bases contains from about 25 to about 50 weight percent of each of the enumerated compounds and the composition contains substantially equal quantities of the base carrier materials. Most preferably the composition contains the following ingredients in the indicated proportions:
- the calcium carbonate, magnesium hydroxide, and aluminum hydroxide are first mixed with water with the water being added a little bit at a time to form a smooth moist mixture having a paste-like consistency and which contains approximately 37 weight percent calcium carbonate, 29.7 weight percent magnesium hydroxide and 33.3 weight percent aluminum hydroxide.
- Dibucaine in a petrolatum base is then added while mixing continuously to maintain a homogenous paste-like consistency.
- the paste containing the systemic bases and the anesthetic just formed is then added to a homogenous mixture of the anhydrous lanolin and the hydrophilic ointment with continuous mixing to insure homogeneity.
- the composition thus prepared has a weight ratio of base carrier materials to nonsystemic bases of about 106:1 since the petrolatum carrier for the dibucaine may generally be classified as a hydrophobic ointment. If the dibucaine is not included, then the ratio of base carrier materials to non-systemic bases would be about 84:1.
- the calcium carbonate and the magnesium hydroxide provide a rapid neutralization of the area under treatment, while the aluminum hydroxide provides a slower but longer lasting neutralization in addition to a mild astringent effect.
- the dibucaine is used essentially for its anesthetic or analgesic effect, i.e., as a topical anesthetic.
- the anhydrous lanolin and the hydrophilic ointment provide a carrier base which facilitates application of the composition to topical areas, assists in maintaining the compound in a semi-solid homogeneous paste-like consistency, and enhances lubrication and absorption by the skin.
- the non-systemic bases which make up a portion of the topical ointment of the instant invention are all readily available compounds.
- Calcium carbonate (CaCO 3 ) is a white powder or colorless crystal having virtually no odor and no taste. It is insoluble in water and alcohol but soluble in acids with the evolution of carbon dioxide.
- Magnesium hydroxide (Mg(OH) 2 ) also known as milk of magnesia, magnesia or magma, is a white powder having no odor, is soluble in solutions of ammonium salts and dilute acids, and is insoluble in water and alcohol.
- Aluminum hydroxide (Al 2 O 3 .3H 2 O or Al(OH) 3 ), also known as aluminum trihydrate, aluminum hydrate, hydrated alumina or hydrated aluminum oxide, generally exists in the form of a white crystalline powder, granules or balls. It is insoluble in water and soluble in mineral acids and caustic soda.
- Dibucaine hydrochloride (2-butoxy-N-(2-diethylaminoethyl) cinchoninamide hydrochloride), can be prepared by a process disclosed in U.S. Pat. No. 1,825,623.
- the dibucaine hydrochloride is incorporated at a concentration of about 0.5 to about 2%, preferably about 1%, in a carrier which is preferably petrolatum but can also be a cream or an oil which is pharmaceutically acceptable for topical application.
- Anhydrous lanolin is the purified wool fat of sheep which consists of cholesteryl and isocholesteryl esters of higher fatty acids.
- the preparation of esterified or so called modified lanolins which are clearly soluble in mineral oils is described by Conrad and Motiuk in U.S. Pat. No. 2,725,334.
- the compound itself is a tenacious, semi-solid fat having a very slight odor and which melts at between 38° and 42° C. It is insoluble in water but will mix with water without separation in a ratio of about 2 parts water to 1 part lanolin.
- Lanolin is a neutral, tenacious, non-irritating, non-volatile base for ointments and creams which is more rapidly absorbed by the skin than most other ointment bases.
- the difference between anhydrous lanolin and lanolin is that ordinary lanolin, which is hydrous wool fat, contains between 25 and 30% water. Since it has been found in the course of experimentation with the composition of the instant invention that water is not advantageous to the healing process, that is, it does not freely promote but rather hinders the healing process, it is preferred to use the anhydrous lanolin.
- a hydrophilic ointment is an ointment which has an affinity for water, that is, the same is capable of uniting with or dissolving in water.
- Such ointment can be made of any suitable composition which can be utilized as a carrier material for the active constituents of the composition.
- these ointments have a mineral oil or petrolatum base and may optionally contain surfactants to assist in maintaining and forming homogeneous mixtures.
- Petrolatum a paraffin jelly commonly referred to as Vaseline (a registered trademark of the Vick Company), is a purified mixture of semi-solid hydrocarbons, chiefly of the methane series.
- the compound is yellowish to light amber or white in color and comprises a semi-solid, unctuous mass which has virtually no odor and no taste. It melts at approximately 38° to 54° C and is insoluble in water and alcohol. It is used generally as an ointment base, as a lubricant or as a protective dressing.
- the method of treating injuries to the skin utilizing the composition of the instant invention involves first thoroughly cleaning the wound, or the specifically affected area, with an antiseptic. Many antiseptics will do, however, in the process of the instant invention, hydrogen peroxide (3%) is preferred. After such cleansing, the wound is then rinsed thoroughly with an abundance of preferably luke warm water. The affected area is then dried thoroughly and cleansed with a sterile absorbent, such as cotton swabs or gauze pads to remove as much moisture as possible. The affected area, such as the ulcer crater, is then generously packed with the topical ointment composition and covered with a sterile dressing. The procedure is repeated as required, generally about every 12 hours. After each application, when removing the dressing to reapply the ointment, the ointment applied will have caked and can generally be removed from the ulcer crater in bulk form.
- an antiseptic Many antiseptics will do, however, in the process of the instant invention, hydrogen peroxide (3%) is preferred.
- additives, modifiers, or selected therapeutic substances may be added to the instant composition with the proviso that they are not added in amounts such that the effectiveness of the inventive composition is hindered or to such a degree that the composition becomes pharmaceutically unacceptable.
- topical ointment composition of the present invention Various preferred forms of the topical ointment composition of the present invention are described in the following examples:
- the calcium carbonate, magnesium hydroxide, and the aluminum hydroxide are substantially insoluble in water.
- a paste was formed therefrom by adding a little water at a time to form a relatively homogeneous dispersion thereof.
- the dibucaine (1%) which is provided in a petrolatum base, was then added with mixing to obtain a smooth homogeneous mixture.
- the anhydrous lanolin and the hydrophilic ointment were then mixed to provide a homogeneous composition which was blended with the dispersion of the calcium carbonate, the magnesium hydroxide, the aluminum hydroxide and the dibucaine. The entire composition was mixed thoroughly to insure a homogeneous dispersion of all of the ingredients.
- the calcium carbonate and the magnesium hydroxide provide a relatively rapid neutralization of the area under treatment.
- the aluminum hydroxide provides a slower longer lasting neutralization in addition to a mild astringent effect.
- the 1% dibucaine hydrochloride dispersed in petrolatum is used for its analgesic or anesthetic effect and the amount may be varied to increase or decrease the anesthetic effect depending on the condition being treated.
- the anhydrous lanolin and the hydrophilic ointment are utilized to provide a base for the composition which facilitates its application and retention in the area of treatment.
- a patient was discharged from a hospital after a three week stay during which the patient had developed two large decubitus ulcers on the right buttock.
- the ulcers were each approximately three-quarters of an inch deep, were conical in shape, had a strong displeasing odor and a serous exudate and exhibited some gangrenous tissue around the edges of the normal skin.
- This patient was treated for three or four months with various known topical creams or ointments of the type generally used to treat this type of lesion.
- These topical creams and ointments included Furacin, Elase ointment, Oxylone cream, Mycolog and Neosporin. During the course of the treatment with the foregoing ointments there was no apparent improvement in the condition.
- the specific method of treatment using the topical ointment composition noted above involved first cleansing each crater with a solution of hydrogen peroxide (3%) and thereafter washing the same with a large volume of luke warm water followed by drying thoroughly with a soft absorbent material such as cotton or gauze to remove exudate and any necrotic tissue.
- the ulcer craters were then packed thoroughly with the topical ointment composition prepared above and were covered with gauze pads.
- the patient was advised to reapply the ointment with a new dressing at approximately 12 hour intervals. After the first 12 hour period the dressing was removed and it was found that the ointment had solidified such that the same could be removed from each ulcer crater in a dry solid mass.
- Example III The composition of Example III was applied initially, after which the patient noted an immediate cooling effect and a loss of pain and was able to open his eyelids all of the way shortly after the first treatment. The treatment was continued using the formula of Example III for three (3) days after which time the patient was seen again.
- the skin at this time was smooth and the edema had subsided; however, a slight bit of redness was still present.
- the patient was given a modified formula similar to the composition of Example III except for a 66% reduction in the concentration of the dibucaine hydrochloride to reduce any irritation which might have been caused thereby. After four days of treatment with such modified topical ointment composition of the instant invention, all symptoms had subsided and the affected areas appeared normal.
- the patient was instructed carefully regarding the correct procedure as to treatment of the dermatitis, i.e., cleansing the affected area and allowing it to dry thoroughly prior to the application of the ointment.
- the patient was also directed to use no soap and to cleanse the affected area with the antiacid composition noted in Example III, followed by rinsing with warm water and thorough drying prior to application of the ointment. Within 48 hours the itching and redness had subsided.
- Example II The composition described in Example II was used to treat diaper rashes of varying severity using the procedure for application outlined above.
- the condition in all cases was considerably improved, if not totally cured, after multiple applications of the topical ointment composition.
- the ointment applied to the genito-rectal areas apparently forms a protective film over the skin and tends to neutralize the acidity of the urine prior to its coming into contact with the epidermis.
- results were noted in cases of vaginitis and/or pruritis vulvae where the condition was considerably alleviated, if not cured completely, by application of the ointment of Example II to the affected areas.
- Preapplication of the antiacid suspension was not necessary as in some of the previous Examples.
- a patient suffering from herpes simplex indicated by dry cracked lips and drying of the nasal mucosa with patches of erythema along the outer edge of the nostrils was treated with the topical ointment of the present invention.
- Repeated application of the topical ointment composition described in Example II resulted in a complete healing of the affected area.
- the patient had received first, second and third degree burns on the left leg extending from the mid-calf to the upper thigh.
- the patient was treated with whirlpool baths and Furacin ointment and little or no improvement was observed.
- the burned area was generally raw with some slight scab formation and had a serous exudate emerging from the raw areas.
- four of the largest burned areas exhibited some gangrenous tissue around the edges.
- the affected area was cleansed thoroughly with a lukewarm solution of 3% hydrogen peroxide and was debrided of exudate and necrotic tissue within the affected areas.
- the burned area was then washed with lukewarm water and was thoroughly dried prior to application of the topical ointment composition of Example III.
- the relief felt by the patient was almost immediate.
- the wound was redressed each 12 hours and it was noticed that with each subsequent redressing of the wound the affected areas became easier to clean and the ointment which had been previously applied to the affected areas did not adhere in any way.
- the wounds appeared clean and small patches of newly formed tissue could be seen.
- the topical ointment composition of Example II was used and the affected area was cleansed prior to each application with the dispersion of antacids described in Example III instead of the warm hydrogen peroxide solution.
- the present invention deals with the formulation of an ointment composition for topical application having the ability to bring the acid-base balance of the skin to a point where healing from within can take place. It has been shown, supra, that the topical ointment of the instant invention can be used for virtually any skin irritation, whether minor or severe, and apparently provides treatment by adjusting the pH of the affected area to a point where normal healthy tissue can be formed.
- a carefully balanced formulation of non-systemic hydroxides of magnesium and aluminum and a carbonate of calcium is provided in an aqueous suspension having a pH of approximately 8 to approximately 10.
- the aqueous suspension is then combined with an anhydrous lanolin based carrier material and a hydrophilic ointment based carrier material.
- the composition also may contain dibucaine hydrochloride which functions as a topical anesthetic and reduces the attendant discomfort.
- the calcium carbonate is included for its rapid neutralizing power and length of neutralization.
- the aluminum hydroxide acts as a buffering antacid producing a slower neutralization reaction and this compound also exhibits an astringent quality.
- the magnesium hydroxide provides antacid properties and also provides the ointment with a smooth, soothing texture which is pleasing to the skin along with cleansing properties.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A topical ointment composition is provided which includes a mixture of non-systemic bases comprising calcium carbonate, magnesium hydroxide, and aluminum hydroxide. The composition also includes an anhydrous lanolin base carrier material and a hydrophilic ointment base carrier material, and the ointment composition is effective to essentially adjust the acid-base balance at the area of topical application to a point which corresponds with normal healthy body tissue. The composition may further include a compound having pharmaceutically acceptable anesthetic properties. In addition to the topical ointment composition, a method is provided for treating skin injuries involving inflammation or destruction of tissue, such as decubitus ulcers, varicose ulcers and burns, which method involves preparing the above noted composition and applying it to the affected area.
Description
This is a continuation of copending application Ser. No. 476,294, filed June 4, 1974, now abandoned.
1. Field of the Invention
This invention relates to the direct treatment of injured mammalian tissue, for example, abraded, lacerated or ulcerated tissues, through the use of a topical ointment composition which has the capacity of adjusting the acid-base balance of the area to which the composition is applied to a point where healing from within can take place.
2. Prior Observations
The skin, supporting body tissues, connective tissues and viscera are subject to a variety of irritations, infections and injuries. These often result in the disruption of the continuity, configuration and appearance of normal tissues and may appear as areas of ulceration, necrosis, contusion, laceration, inflammation and tumefaction. Conventional compositions for dressings to be applied to such irritated or injured tissues often act as foreign bodies and are frequently themselves a source of irritation which may impede the healing process and promote infection.
The skin is composed of two layers, i.e., the epidermis or cuticle and the dermis or true skin. The epidermis is a thin outer layer composed of stratified epithelium. The cells in the deepest portion of the epidermis, the Malpighian layer, multiply and, in growing, push the older cells of the epidermis upward toward the surface. As these cells move upwardly they become flattened and plate-like in shape. The epidermis, being generally devoid of blood vessels, is dependent for its nutrition upon the vessels found in the dermis. These vessels end as capilliary loops in the papillae of the dermis. The more superficial cells of the epidermis, being far removed from the nutrient supply, gradually degenerate and their proteins are transformed into keratin. This process, termed keratinization, results in the death of the cells. Keratin is the most insoluble of all proteinaceous material which gives the upper layer of the skin (the stratum corneum) a horn like consistency. During the life process, the outermost dead scales of keratin are gradually shed and replaced by more recently keratinized cells. Keratin also is found in the appendages of the skin, that is, in the nails and hair. In the lower animals it is found in the horns, hoofs and claws. In the palms of the hands and soles of the feet, the epidermis is much thicker than elsewhere.
The true skin, corium or dermis, lies just below the Malpighian layer and is formed of loose connective tissue which sends little elevations known as papillae into the cuticle or epidermis. At its deepest portions the dermis gradually passes into the areolar subcutaneous tissue. In the dermis, or more especially, in the subcutaneous tissue, a variable amount of adipose tissue exists. While the epidermis is not supplied with blood vessels, the dermis is very vascular and the sebaceous (oil) and sudoriferous (sweat) glands are located in the dermis. The oil glands, which reside in the deeper parts of the skin, are distributed in all areas of the body except the soles of the feet and the palms of the hands. The sebaceous secretion, known as sebum, contains fats, proteins, water, salt, and remnants of epithelial cells. The sebum protects the structures of the skin and the hair against intolerable drying and breakage by oiling the same and thus the physical integrity of the skin is preserved. Additionally, the sebum prevents excessive loss of water by the skin.
One of the primary functions of the skin is protection. The epidermis of the skin, which is composed of hard, resistant cells, forms the bodies first line of defense against mechanical and chemical injuries and, above all, against bacterial invasion, because the unbroken skin is substantially germ proof. This protection is evidenced by the frequent infections which occur when the skin is injured so as to expose the underlying tissues. Recently, it has been demonstrated that the skin not only serves as a mechanical barrier but that it also possesses immunizing powers. Additionally, the sense organs for heat and cold, touch and pain are located in the dermis. Further, the skin helps to regulate body temperature through vasomotor reactions of blood vessels and through evaporation of perspiration. Perspiration sometimes has acidic and sometimes basic properties and its odor may be very marked and differs in various regions of the body. The skin also plays an important part in water metabolism, calcium metabolism and to a lesser degree, excretion and adsorption.
Various injuries which effect the skin include those caused by allergic reactions, mechanical impact or abrasion, chemical attack, heat, etc. These may result in disruption of normal tissue continuity, configuration and appearance and may appear as areas of ulceration, necrosis, contusion, laceration, inflammation and tumefaction.
The terms above, for the purposes of this specification, are intended to have the following meanings:
Ulcer -- is a local defect or excavation of the surfaces of an organ produced by sloughing of necrotic inflammatory tissue;
Decubitus ulcer -- is an ulceration caused by prolonged pressure on a body area in a patient confined to bed;
Necrosis -- is the death of a cell as a result of a disease or injury;
Contusion -- is an injury to tissues without breakage of the skin;
Laceration -- is a wound produced by tearing;
Inflammation -- is a specific tissue response to injury by living agents, or to electrical, chemical or mechanical trauma, evidenced by vascular dilatation, fluid exudation, or accumulation of lukocytes or any combination of the three;
Tumefaction -- is a swelling or puffiness;
Rash -- is a temporary erruption on the skin;
Diaper Rash -- is a dermatitis of the gluteal region of infants.
Erythema -- is a congestive or exudative redness of the skin caused by hyperima which is an excess of blood in a particular part;
Edema -- is an abnormal accumulation of fluid in the intracellular spaces of the body;
Eczema -- is generally a skin disease having associated therewith, itching and redness.
Various compositions useful for treatment of injuries to the skin are known in the prior art. Among these known compositions are the following:
Furacin (a registered trademark of Eaton Laboratory, Norwich, New York) is a topical cream containing nitrofurazone in a base consisting of glycerine, cetyl alcohol, mineral oil, an ethoxylated fatty alcohol, methylparaben, propylparaben and water. The water miscible base is self-emulsifying in various body fluids. The topical cream finds use in the treatment or prophylaxis of the surface bacterial infections.
Elase Ointment (a registered trademark of the Parke-Davis Company, Detroit, Michigan) is a combination of two lytic enzymes, fibrinolysin and desoxyribonuclease, in an ointment. The fibrinolysin component is derived from bovine plasma and the desoxyribonuclease is isolated in a purified form from bovine pancreas. The combination of these two enzymes is based on the observation that purulent exudates consist largely of fibrinous material and nucleoprotein. Desoxyribonuclease attacks the desoxyribonucleic acid (DNA) and fibrinolysin attacks principally fibrin of blood clots and fibrinous exudates. Elase is used topically as a debriding agent in a variety of inflammatory and infected lesions including (1) general surgical wounds, (2) ulcerative lesions, i.e., trophic, decubitus, stasis, arteriosclerotic; and (3) second and third degree burns.
Oxylone (a registered trademark of the Upjohn Company, Kalamazoo, Michigan) contains fluorometholone, which is a steroid, in addition to glyceryl monostearate, spermaceti, polyethylene glycol emulsifier, water and preservatives. This material includes a water soluble vanishing cream base designed for use on exposed regions of the skin such as the face and hands and is allegedly effective because of the anti-inflammatory, anti-pruritic and vasoconstrictive action provided by the steroid, fluorometholone. The cream is used to obtain symptomatic relief and adjunctive management of various dermatoses including sunburn, eczema and diaper rash.
Mycolog (a registered trademark of E. R. Squibb & Sons, Princeton, New Jersey) is a dermatologic preparation used in cases of dermatitis complicated with a superficial bacterial infection. Among other things, it is anti-fungal and anti-bacterial and contains nystatin, neomycin sulfate, gramicidin, and triamcinolone acetonide either in a vanishing cream base or in a protective base of polyethylene and mineral oil gel.
Neosporin (a registered trademark of the Burroughs-Wellcome Company, North Carolina) provides anti-bacterial action against commonly occuring bacteria known to be topical invaders. The ointment contains neomycin sulfate, zinc bacitracin and polymyxin B-sulfate.
The foregoing compositions, even though many of the same include fungicides, bacteriacides or hazardous steroids, still do not provide either the degree or speed of healing which is obtained with the composition of the instant invention in the treatment of many injuries to the skin, as will be clearly shown in the examples infra.
It is a principal object of the instant invention to provide a topical ointment composition useful for treating injuries to the skin which result in ulcerated, lacerated or abraded tissue. In this connection it is a principal aim of the invention to provide a method for producing such a composition.
It is a further object of the present invention to provide a filling or cementing material for injured tissue which is soft, flexible, protective and non-irritating and which provides a temporary nucleus to facilitate the growth of replacement tissues for healing purposes.
Other objects and advantages of the present invention including stability, convenience, economy and adaptability for use in conjunction with various known materials will be apparent from the following detailed description of the preferred embodiments thereof.
Briefly, the composition of the instant invention is useful in treating various injuries to the skin which result in ulcerated, lacerated or abraded tissue and in particular the composition is useful in the treatment of decubitus ulcers. The composition is in the form of a topical ointment and contains a mixture of non-systemic bases, a lanolin base carrier material and a hydrophilic ointment carrier material. The mixture of bases is present in the composition in an amount effective to adjust the acid-base balance of the area of topical application to a point which corresponds with normal, healthy body tissue. Optionally the topical ointment may also include a compound having anesthetic properties.
More specifically, the mixture of non-systemic bases consists essentially of from about 7 to about 82 weight percent calcium carbonate, from about 5 to about 77 weight percent magnesium hydroxide and from about 6 to about 80 weight percent aluminum hydroxide and the percentages of these enumerated bases total approximately 100 percent of the mixture thereof. Moreover, the weight ratio of the anhydrous lanolin base carrier material to the hydrophilic ointment base carrier material in the composition ranges from approximately 2:1 to approximately 1:2. Additionally, the weight ratio of base carrier materials to non-systemic bases in said composition should be in the range of about 21:1 to 213:1 to achieve the best results. The compound having anesthetic properties may be, for example, dibucaine, benzocaine, lidocaine, pramoxine hydrochloride, etc. However, dibucaine is preferred.
Additionally, the instant invention provides a method for preparing such a topical ointment composition which comprises forming a paste comprising a mixture of non-systemic bases including calcium carbonate, magnesium hydroxide and aluminum hydroxide and a sufficient amount of water to provide a smooth, moist paste and separately admixing an anhydrous lanolin base carrier material and a hydrophilic ointment base carrier material in a weight ratio ranging from approximately 2:1 to approximately 1:2. Thereafter the admixture of base carrier materials is blended with the paste to obtain a workable homogeneous paste.
In the preferred embodiment of the invention, a mixture of non-systemic bases consisting essentially of about 7 to about 82 weight percent calcium carbonate, from about 5 to about 77 weight percent magnesium hydroxide and from about 6 to about 80 weight percent aluminum hydroxide is provided. The percentages of the components in the mixture total approximately 100 percent thereof and a sufficient amount of water is added to the mixture to provide a smooth, moist paste which preferably has a pH in the range of from about 8.0 to about 9.5. An anhydrous lanolin base carrier material and a hydrophilic ointment base carrier material are admixed in a weight ratio ranging from approximately 2:1 to approximately 1:2 and the mixture of bases is blended with the admixture of base carrier materials. The blended composition contains an amount of the basic paste effective to essentially adjust the acid-base balance at the area of topical application to a point which corresponds with normal, healthy body tissue and in this connection, the weight ratio of base carrier materials to nonsystemic bases in said composition should preferably be in the range of from about 21:1 to about 213:1.
More preferably the admixture of bases contains from about 25 to about 50 weight percent of each of the enumerated compounds and the composition contains substantially equal quantities of the base carrier materials. Most preferably the composition contains the following ingredients in the indicated proportions:
______________________________________
Calcium carbonate 250 mg
Magnesium Hydroxide 200 mg
Aluminum Hydroxide 225 mg
Dibucaine (1% in Petrolatum*)
150 mg
Anhydrous lanolin 28.35 gms
Hydrophilic Ointment 28.35 gms
*Petrolatum 15 gms
Water 10 cc
______________________________________
In mixing the above ingredients to yield a topical ointment, the calcium carbonate, magnesium hydroxide, and aluminum hydroxide are first mixed with water with the water being added a little bit at a time to form a smooth moist mixture having a paste-like consistency and which contains approximately 37 weight percent calcium carbonate, 29.7 weight percent magnesium hydroxide and 33.3 weight percent aluminum hydroxide. Dibucaine in a petrolatum base is then added while mixing continuously to maintain a homogenous paste-like consistency. The paste containing the systemic bases and the anesthetic just formed is then added to a homogenous mixture of the anhydrous lanolin and the hydrophilic ointment with continuous mixing to insure homogeneity. The composition thus prepared has a weight ratio of base carrier materials to nonsystemic bases of about 106:1 since the petrolatum carrier for the dibucaine may generally be classified as a hydrophobic ointment. If the dibucaine is not included, then the ratio of base carrier materials to non-systemic bases would be about 84:1.
When the composition is applied topically, the calcium carbonate and the magnesium hydroxide provide a rapid neutralization of the area under treatment, while the aluminum hydroxide provides a slower but longer lasting neutralization in addition to a mild astringent effect. The dibucaine is used essentially for its anesthetic or analgesic effect, i.e., as a topical anesthetic. The anhydrous lanolin and the hydrophilic ointment provide a carrier base which facilitates application of the composition to topical areas, assists in maintaining the compound in a semi-solid homogeneous paste-like consistency, and enhances lubrication and absorption by the skin.
The non-systemic bases which make up a portion of the topical ointment of the instant invention are all readily available compounds. Calcium carbonate (CaCO3) is a white powder or colorless crystal having virtually no odor and no taste. It is insoluble in water and alcohol but soluble in acids with the evolution of carbon dioxide.
Magnesium hydroxide (Mg(OH)2), also known as milk of magnesia, magnesia or magma, is a white powder having no odor, is soluble in solutions of ammonium salts and dilute acids, and is insoluble in water and alcohol.
Aluminum hydroxide (Al2 O3.3H2 O or Al(OH)3), also known as aluminum trihydrate, aluminum hydrate, hydrated alumina or hydrated aluminum oxide, generally exists in the form of a white crystalline powder, granules or balls. It is insoluble in water and soluble in mineral acids and caustic soda.
Dibucaine hydrochloride (2-butoxy-N-(2-diethylaminoethyl) cinchoninamide hydrochloride), can be prepared by a process disclosed in U.S. Pat. No. 1,825,623. The dibucaine hydrochloride is incorporated at a concentration of about 0.5 to about 2%, preferably about 1%, in a carrier which is preferably petrolatum but can also be a cream or an oil which is pharmaceutically acceptable for topical application.
Anhydrous lanolin is the purified wool fat of sheep which consists of cholesteryl and isocholesteryl esters of higher fatty acids. The preparation of esterified or so called modified lanolins which are clearly soluble in mineral oils is described by Conrad and Motiuk in U.S. Pat. No. 2,725,334. The compound itself is a tenacious, semi-solid fat having a very slight odor and which melts at between 38° and 42° C. It is insoluble in water but will mix with water without separation in a ratio of about 2 parts water to 1 part lanolin. Lanolin is a neutral, tenacious, non-irritating, non-volatile base for ointments and creams which is more rapidly absorbed by the skin than most other ointment bases. The difference between anhydrous lanolin and lanolin is that ordinary lanolin, which is hydrous wool fat, contains between 25 and 30% water. Since it has been found in the course of experimentation with the composition of the instant invention that water is not advantageous to the healing process, that is, it does not freely promote but rather hinders the healing process, it is preferred to use the anhydrous lanolin. It should also be noted at this point that in preparation of the composition, only enough water is used to provide a smooth homogeneous paste of the non-systemic bases prior to admixing the latter with the anhydrous lanolin and the hydrophilic ointment. Only enough water should be used in the composition to maintain the same in a paste-like consistency to facilitate the topical application thereof.
A hydrophilic ointment is an ointment which has an affinity for water, that is, the same is capable of uniting with or dissolving in water. Such ointment can be made of any suitable composition which can be utilized as a carrier material for the active constituents of the composition. Generally, these ointments have a mineral oil or petrolatum base and may optionally contain surfactants to assist in maintaining and forming homogeneous mixtures. Petrolatum, a paraffin jelly commonly referred to as Vaseline (a registered trademark of the Vick Company), is a purified mixture of semi-solid hydrocarbons, chiefly of the methane series. The compound is yellowish to light amber or white in color and comprises a semi-solid, unctuous mass which has virtually no odor and no taste. It melts at approximately 38° to 54° C and is insoluble in water and alcohol. It is used generally as an ointment base, as a lubricant or as a protective dressing.
The method of treating injuries to the skin utilizing the composition of the instant invention involves first thoroughly cleaning the wound, or the specifically affected area, with an antiseptic. Many antiseptics will do, however, in the process of the instant invention, hydrogen peroxide (3%) is preferred. After such cleansing, the wound is then rinsed thoroughly with an abundance of preferably luke warm water. The affected area is then dried thoroughly and cleansed with a sterile absorbent, such as cotton swabs or gauze pads to remove as much moisture as possible. The affected area, such as the ulcer crater, is then generously packed with the topical ointment composition and covered with a sterile dressing. The procedure is repeated as required, generally about every 12 hours. After each application, when removing the dressing to reapply the ointment, the ointment applied will have caked and can generally be removed from the ulcer crater in bulk form.
Various additives, modifiers, or selected therapeutic substances may be added to the instant composition with the proviso that they are not added in amounts such that the effectiveness of the inventive composition is hindered or to such a degree that the composition becomes pharmaceutically unacceptable.
Various preferred forms of the topical ointment composition of the present invention are described in the following examples:
The following constituents were mixed to provide an example of the instant composition:
______________________________________
Calcium carbonate 250 mg
Magnesium Hydroxide 200 mg
Aluminum Hydroxide 225 mg
Dibucaine (1% in petrolatum*)
100 mg
Anhydrous Lanolin 28.35 gm
Hydrophilic Ointment 28.35 gm
*Petrolatum 10 gm
Water 5 cc
______________________________________
The calcium carbonate, magnesium hydroxide, and the aluminum hydroxide are substantially insoluble in water. To assist in the dispersion of these components in the base carrier material, a paste was formed therefrom by adding a little water at a time to form a relatively homogeneous dispersion thereof. The dibucaine (1%), which is provided in a petrolatum base, was then added with mixing to obtain a smooth homogeneous mixture. The anhydrous lanolin and the hydrophilic ointment were then mixed to provide a homogeneous composition which was blended with the dispersion of the calcium carbonate, the magnesium hydroxide, the aluminum hydroxide and the dibucaine. The entire composition was mixed thoroughly to insure a homogeneous dispersion of all of the ingredients.
The calcium carbonate and the magnesium hydroxide provide a relatively rapid neutralization of the area under treatment. The aluminum hydroxide, however, provides a slower longer lasting neutralization in addition to a mild astringent effect. The 1% dibucaine hydrochloride dispersed in petrolatum is used for its analgesic or anesthetic effect and the amount may be varied to increase or decrease the anesthetic effect depending on the condition being treated. The anhydrous lanolin and the hydrophilic ointment are utilized to provide a base for the composition which facilitates its application and retention in the area of treatment.
A patient was discharged from a hospital after a three week stay during which the patient had developed two large decubitus ulcers on the right buttock. The ulcers were each approximately three-quarters of an inch deep, were conical in shape, had a strong displeasing odor and a serous exudate and exhibited some gangrenous tissue around the edges of the normal skin. This patient was treated for three or four months with various known topical creams or ointments of the type generally used to treat this type of lesion. These topical creams and ointments included Furacin, Elase ointment, Oxylone cream, Mycolog and Neosporin. During the course of the treatment with the foregoing ointments there was no apparent improvement in the condition. In fact, the condition worsened and the patient was advised to make arrangements for skin grafting. Prior to the grafting it was suggested that the patient utilize the ointment of the present invention which composition in this instance was as follows: (prepared in accordance with the method of Example I)
______________________________________
Calcium Carbonate 250 mg
Magnesium Hydroxide 200 mg
Aluminum Hydroxide 225 mg
Dibucaine (1% in Petrolatum*)
150 mg
Anhydrous Lanolin 28.35 gm
Hydrophilic Ointment 28.35 gm
*Petrolatum 15 gm
Water 10 cc
______________________________________
The specific method of treatment using the topical ointment composition noted above involved first cleansing each crater with a solution of hydrogen peroxide (3%) and thereafter washing the same with a large volume of luke warm water followed by drying thoroughly with a soft absorbent material such as cotton or gauze to remove exudate and any necrotic tissue. The ulcer craters were then packed thoroughly with the topical ointment composition prepared above and were covered with gauze pads. The patient was advised to reapply the ointment with a new dressing at approximately 12 hour intervals. After the first 12 hour period the dressing was removed and it was found that the ointment had solidified such that the same could be removed from each ulcer crater in a dry solid mass. The procedure was repeated and healthy pink tissue was observed in the ulcer craters within 48 hours after the first treatment with the topical ointment composition. It was noted during the treatment that the use of any outside aqueous compositions, such as soap or plain water, considerably retarded healing and enhanced irritation. The ulcer craters were essentially completely healed in four (4) weeks with virtually no scar tissue. It was also noted during the treatment of the decubitus ulcers that the wound did not require cleansing during the period of treatment, that is, the topical ointment composition of the instant invention acted effectively as a cleansing agent and no other external agents were required during treatment to maintain the wound or the injured tissue in a cleansed state.
A male construction worker who had suffered from chronic contact dermatitis for 8 to 9 years due to constant exposure to varying conditions of weather, experienced dry, cracked areas and scaling of the epidermis accompanied by some throbbing and partial loss of feeling. The patient was advised to clean his hands with a paste comprising a suspension of 250 mg of calcium carbonate, 200 mg of magnesium hydroxide and 225 mg of aluminum hydroxide in 10 cc of water, followed by rinsing with lukewarm water and thorough drying. The following ointment composition, prepared in accordance with the procedure outlined in Example I above, was then applied to the affected areas every 12 hours:
______________________________________ Calcium Carbonate 1,000 mg Magnesium Hydroxide 800 mg Aluminum Hydroxide 900 mg Dibucaine Hydrochloride (1% in Petrolatum*) 600 mg Anhydrous Lanolin 28.35 gm Hydrophilic Ointment 28.35 gm Water 40 cc *Petrolatum 60 gm ______________________________________
After one week of continued therapy using this composition, the previously dried, cracked and scaling areas of the epidermis were clean and smooth and there was a complete absence of scaling. In addition the throbbing had been relieved and the sense of touch had been renewed.
In this instance, a patient suffering from an acute, chemically induced, allergic contact dermatitis experienced pruritus, edema, erythema and pain. The areas of the epidermis involved were the cheeks, where scaling, edema and pruritus were noted, and the eyelids where cracking occurred along the outer corners of the eyes. The patient was unable to open his eyelids without severe pulling and pain in the corners of each eye. The composition of Example III was applied initially, after which the patient noted an immediate cooling effect and a loss of pain and was able to open his eyelids all of the way shortly after the first treatment. The treatment was continued using the formula of Example III for three (3) days after which time the patient was seen again. The skin at this time was smooth and the edema had subsided; however, a slight bit of redness was still present. The patient was given a modified formula similar to the composition of Example III except for a 66% reduction in the concentration of the dibucaine hydrochloride to reduce any irritation which might have been caused thereby. After four days of treatment with such modified topical ointment composition of the instant invention, all symptoms had subsided and the affected areas appeared normal.
In this instance, a patient suffering from contact dermatitis of the lower extremities, manifested by itching and redness, was treated for one (1) week with the following topical ointment composition which was prepared in accordance with the method of Example I:
______________________________________ Calcium Carbonate 250 mg Magnesium Hydroxide 200 mg Aluminum Hydroxide 225 mg Dibucaine Hydrochloride (1% in petrolatum*) 300 mg Anhydrous Lanolin 28.35 gm Hydrophilic Ointment 28.35 gm *Petrolatum 30 gm Water 10 cc ______________________________________
The patient was instructed carefully regarding the correct procedure as to treatment of the dermatitis, i.e., cleansing the affected area and allowing it to dry thoroughly prior to the application of the ointment. The patient was also directed to use no soap and to cleanse the affected area with the antiacid composition noted in Example III, followed by rinsing with warm water and thorough drying prior to application of the ointment. Within 48 hours the itching and redness had subsided.
The composition described in Example II was used to treat diaper rashes of varying severity using the procedure for application outlined above. The condition in all cases was considerably improved, if not totally cured, after multiple applications of the topical ointment composition. The ointment applied to the genito-rectal areas apparently forms a protective film over the skin and tends to neutralize the acidity of the urine prior to its coming into contact with the epidermis. Similarly, results were noted in cases of vaginitis and/or pruritis vulvae where the condition was considerably alleviated, if not cured completely, by application of the ointment of Example II to the affected areas. Preapplication of the antiacid suspension was not necessary as in some of the previous Examples.
A patient suffering from herpes simplex indicated by dry cracked lips and drying of the nasal mucosa with patches of erythema along the outer edge of the nostrils was treated with the topical ointment of the present invention. Repeated application of the topical ointment composition described in Example II resulted in a complete healing of the affected area.
In this case, the patient had received first, second and third degree burns on the left leg extending from the mid-calf to the upper thigh. During a 3 to 4 week hospital stay the patient was treated with whirlpool baths and Furacin ointment and little or no improvement was observed. Upon discharge from the hospital, the burned area was generally raw with some slight scab formation and had a serous exudate emerging from the raw areas. In addition, four of the largest burned areas exhibited some gangrenous tissue around the edges. The affected area was cleansed thoroughly with a lukewarm solution of 3% hydrogen peroxide and was debrided of exudate and necrotic tissue within the affected areas. The burned area was then washed with lukewarm water and was thoroughly dried prior to application of the topical ointment composition of Example III. The relief felt by the patient was almost immediate. The wound was redressed each 12 hours and it was noticed that with each subsequent redressing of the wound the affected areas became easier to clean and the ointment which had been previously applied to the affected areas did not adhere in any way. By the third day, the wounds appeared clean and small patches of newly formed tissue could be seen. At this time the topical ointment composition of Example II was used and the affected area was cleansed prior to each application with the dispersion of antacids described in Example III instead of the warm hydrogen peroxide solution. A clean sterile gauze dressing was applied after each subsequent ointment application. The healing was pronounced. The small patches of skin seen after the third treatment began to grow and coalesce forming new skin virtually in the absence of scar tissue. After two weeks of treatment only a small area remained to be healed and complete closure of all other previously raw areas was apparent. The skin at the circumference of each raw area grew toward the center of the wound in the same manner as was noticed in Example II above involving the treatment of the decubitus ulcer.
In this instance a patient suffering from digital eczema, with no improvement after one month of treatment, was treated for three weeks with the topical ointment composition of Example II after which it was noted that complete healing and restoration of the epidermis in the previously affected area had occurred.
The present invention deals with the formulation of an ointment composition for topical application having the ability to bring the acid-base balance of the skin to a point where healing from within can take place. It has been shown, supra, that the topical ointment of the instant invention can be used for virtually any skin irritation, whether minor or severe, and apparently provides treatment by adjusting the pH of the affected area to a point where normal healthy tissue can be formed.
To achieve these properties a carefully balanced formulation of non-systemic hydroxides of magnesium and aluminum and a carbonate of calcium is provided in an aqueous suspension having a pH of approximately 8 to approximately 10. The aqueous suspension is then combined with an anhydrous lanolin based carrier material and a hydrophilic ointment based carrier material. The composition also may contain dibucaine hydrochloride which functions as a topical anesthetic and reduces the attendant discomfort.
In the antacid combination containing calcium carbonate, magnesium hydroxide and aluminum hydroxide, the calcium carbonate is included for its rapid neutralizing power and length of neutralization. The aluminum hydroxide acts as a buffering antacid producing a slower neutralization reaction and this compound also exhibits an astringent quality. The magnesium hydroxide provides antacid properties and also provides the ointment with a smooth, soothing texture which is pleasing to the skin along with cleansing properties.
Claims (13)
1. A topical ointment composition consisting essentially of an admixture of:
a. a mixture of non-systemic bases consisting of from about 7 to about 82 weight percent calcium carbonate, from about 5 to about 77 weight percent magnesium hydroxide and from about 6 to about 80 weight percent aluminum hydroxide, with the proviso that the percentages of said components in said mixture total 100% thereof; and
b. a mixture of carrier materials consisting essentially of anhydrous lanolin and hydrophilic ointment said carrier materials being present in said carrier mixture in a weight ratio of approximately 2:1 to 1:2; said ointment containing a weight ratio of said mixture of 1:21 to 1 to 213, effective to promote growth of normal healthy body tissues.
2. A topical ointment composition as set forth in claim 1 further containing an effective amount of a topical anesthetic.
3. The topical ointment composition as set forth in claim 1 wherein said mixture of bases consists of about 25 to about 50 weight percent of each of said components.
4. The topical ointment composition as set forth in claim 3 wherein said mixture of bases consists of about 37 weight percent calcium carbonate, about 29.7 weight percent magnesium hydroxide and about 33.3 weight percent of aluminum hydroxide.
5. The topical ointment composition as set forth in claim 4 wherein said carrier mixture materials are in substantially equal quantities.
6. A topical ointment composition consisting essentially of an admixture of:
a. a paste comprising a mixture of non-systemic bases consisting of from about 7 to about 82 weight percent calcium carbonate, from about 5 to about 77 weight percent magnesium hydroxide and from about 6 to about 80 weight percent aluminum hydroxide, with the proviso that the percentages of said components in said mixture total 100% thereof, and a sufficient amount of water to present a smooth, moist paste; and
b. a mixture of carrier materials consisting essentially of anhydrous lanolin and hydrophilic ointment, said carrier materials being present in said carrier mixture in a relative weight ratio of approximately 2:1 to 1:2; said ointment containing a weight ratio of said mixture of bases to carrier of 1:21 to 1:213 effective to promote growth of normal healthy body tissue.
7. The topical ointment composition as set forth in claim 6 wherein said paste has a pH of from about 8 to about 9.5.
8. The topical ointment composition as set forth in claim 6 wherein said mixture of bases consists of about 25 to about 50 weight percent of each of said components.
9. The topical ointment composition as set forth in claim 8 wherein said mixture of bases consists of about 37 weight percent calcium carbonate, about 29.7 weight percent magnesium hydroxide and about 33.3 weight percent aluminum hydroxide.
10. The topical ointment composition as set forth in claim 9 wherein said carrier materials are in substantially equal quantities.
11. A topical ointment composition as set forth in claim 6 further containing an effective amount of a topical anesthetic.
12. A topical ointment composition as set forth in claim 10 further containing an effective amount of a topical anesthetic.
13. The topical ointment composition as set forth in claim 6 consisting of: calcium carbonate, 250 parts by weight; magnesium hydroxide, 200 parts by weight; aluminum hydroxide, 225 parts by weight; dibucaine hydrochloride, 100 parts by weight; anhydrous lanolin, 28,350 parts by weight; and hydrophilic ointment, 28,350 parts by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/628,972 US4005191A (en) | 1974-06-04 | 1975-11-05 | Topical ointment composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47629474A | 1974-06-04 | 1974-06-04 | |
| US05/628,972 US4005191A (en) | 1974-06-04 | 1975-11-05 | Topical ointment composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US47629474A Continuation | 1974-06-04 | 1974-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4005191A true US4005191A (en) | 1977-01-25 |
Family
ID=27045138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/628,972 Expired - Lifetime US4005191A (en) | 1974-06-04 | 1975-11-05 | Topical ointment composition |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US4005191A (en) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4265883A (en) * | 1979-10-01 | 1981-05-05 | Cameron Mable R | Composition and process for treating uterine prolapse |
| US4284630A (en) * | 1978-03-22 | 1981-08-18 | Yu Ruey J | Stabilized water-in-oil emulsions |
| WO1987005809A1 (en) * | 1986-04-02 | 1987-10-08 | Dermasciences, Inc. | Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith |
| DE3634714A1 (en) * | 1985-04-16 | 1988-04-14 | Mitsui Norin Co | COMPLEX FROM AN EXTRACT OF TEA LEAVES AND ACTIVE ALUMINUM HYDROXIDE |
| US4784851A (en) * | 1985-03-18 | 1988-11-15 | Rohwer Gary L | Composition for treatment of acidosis in ruminants and method |
| WO1988009665A1 (en) * | 1987-06-01 | 1988-12-15 | Allergan, Inc. | Preservative free ophthalmic ointments |
| EP0335379A3 (en) * | 1988-03-30 | 1990-01-10 | Daiichi Seiyaku Co. Ltd. | Cyclic amp derivative ointments |
| US5143717A (en) * | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
| US5154932A (en) * | 1985-07-05 | 1992-10-13 | The Dow Chemical Company | Antimicrobial positively charged particles |
| WO1994002847A1 (en) * | 1992-07-27 | 1994-02-03 | Invitro International | In vitro test for dermal corrosive properties |
| US5618274A (en) * | 1994-04-08 | 1997-04-08 | Rosenthal; Kenneth J. | Method and device for deep pressurized topical, fornix applied "nerve block" anesthesia |
| WO1998034653A1 (en) * | 1997-02-07 | 1998-08-13 | Queen's University At Kingston | Anaesthetic bone cement |
| WO2001080814A1 (en) * | 2000-04-20 | 2001-11-01 | Profoot, Inc. | Set depth nail notcher with patch system and method for treating nail fungus |
| US20030072724A1 (en) * | 1999-12-16 | 2003-04-17 | Maibach Howard I. | Topical pharmaceutical composition to treat hyperpigmentation of the skin |
| US6572580B2 (en) | 1998-08-06 | 2003-06-03 | Profoot, Inc. | Set depth nail notcher with patch system and method for treating nail fungus |
| US20040013744A1 (en) * | 2002-07-17 | 2004-01-22 | Goulbourne Mary J. | Ointment composition for treating decubitus ulcers and methods for its making and its use |
| US6713527B2 (en) * | 1997-02-07 | 2004-03-30 | Queen's University At Kingston | Anaesthetic bone cement |
| US20040076671A1 (en) * | 2002-10-21 | 2004-04-22 | Aletha Tippett | Methods and compositions for topical wound treatment |
| US20050043253A1 (en) * | 2003-08-19 | 2005-02-24 | Cook Bradley R. | Use of wound healing compositions for prevention of infections and allergies |
| US20060034951A1 (en) * | 2002-05-28 | 2006-02-16 | Kwak Tae H | Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| US20060040002A1 (en) * | 2004-08-17 | 2006-02-23 | Boitano Suzanne M | Anti-itch composition |
| US20060121100A1 (en) * | 2004-12-06 | 2006-06-08 | Opremcak E M | Bandage and method for vital bleaching of skin |
| EP2482807A2 (en) | 2009-10-02 | 2012-08-08 | The Brigham and Women's Hospital, Inc. | Compositions and methods of prophylaxis for contact dermatitis |
| US20130011494A1 (en) * | 2011-07-10 | 2013-01-10 | Mohammad Rahimi | Composition for treating decubitus ulcers in diabetic and non-diabetic patients |
| US20190060281A1 (en) * | 2017-08-24 | 2019-02-28 | Jessica S. WHITTLE | Compositions and treatment methods for diaper dermatitis and skin irritation |
| RU2740453C2 (en) * | 2014-07-31 | 2021-01-14 | Аморфикал Лтд. | Non-aqueous liquid and semi-solid compositions of amorphous calcium carbonate |
| US20230346880A1 (en) * | 2022-02-25 | 2023-11-02 | University Of South Florida | Topical formulations for treatment of hypergranulation tissue |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US139315A (en) * | 1873-05-27 | Improvement in medical compounds or ointments | ||
| US1375220A (en) * | 1919-09-13 | 1921-04-19 | Leist Jean Ignaz | Composition for repelling insects |
| US1999161A (en) * | 1935-04-23 | Skin cream containing magnesium | ||
| US3137622A (en) * | 1957-12-23 | 1964-06-16 | Kline | Topical therapeutic composition |
| US3265571A (en) * | 1965-04-08 | 1966-08-09 | Barnes Hind Pharm Inc | Thixotropic acne vulgaris composition |
-
1975
- 1975-11-05 US US05/628,972 patent/US4005191A/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US139315A (en) * | 1873-05-27 | Improvement in medical compounds or ointments | ||
| US1999161A (en) * | 1935-04-23 | Skin cream containing magnesium | ||
| US1375220A (en) * | 1919-09-13 | 1921-04-19 | Leist Jean Ignaz | Composition for repelling insects |
| US3137622A (en) * | 1957-12-23 | 1964-06-16 | Kline | Topical therapeutic composition |
| US3265571A (en) * | 1965-04-08 | 1966-08-09 | Barnes Hind Pharm Inc | Thixotropic acne vulgaris composition |
Non-Patent Citations (4)
| Title |
|---|
| Handbook of Non-Prescription Drugs, (1973), pp. 145-146. * |
| Husa's Pharmaceutical Dispensing, (1966), pp. 144-151. * |
| Physician's Desk Reference, (PDR), (1971), p. 674. * |
| Sagarin, Cosmetics, Science and Technology, (1957), pp. 1163-1164. * |
Cited By (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284630A (en) * | 1978-03-22 | 1981-08-18 | Yu Ruey J | Stabilized water-in-oil emulsions |
| US4265883A (en) * | 1979-10-01 | 1981-05-05 | Cameron Mable R | Composition and process for treating uterine prolapse |
| US4784851A (en) * | 1985-03-18 | 1988-11-15 | Rohwer Gary L | Composition for treatment of acidosis in ruminants and method |
| DE3634714A1 (en) * | 1985-04-16 | 1988-04-14 | Mitsui Norin Co | COMPLEX FROM AN EXTRACT OF TEA LEAVES AND ACTIVE ALUMINUM HYDROXIDE |
| US4913909A (en) * | 1985-04-16 | 1990-04-03 | Mitsui Norin Co., Ltd. | Complex of tea-leaf extract and active aluminum hydroxide |
| US5154932A (en) * | 1985-07-05 | 1992-10-13 | The Dow Chemical Company | Antimicrobial positively charged particles |
| WO1987005809A1 (en) * | 1986-04-02 | 1987-10-08 | Dermasciences, Inc. | Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith |
| US4847083A (en) * | 1986-04-02 | 1989-07-11 | Dermasciences, Inc. | Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith |
| WO1988009665A1 (en) * | 1987-06-01 | 1988-12-15 | Allergan, Inc. | Preservative free ophthalmic ointments |
| US5143717A (en) * | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
| EP0335379A3 (en) * | 1988-03-30 | 1990-01-10 | Daiichi Seiyaku Co. Ltd. | Cyclic amp derivative ointments |
| US5096891A (en) * | 1988-03-30 | 1992-03-17 | Daiichi Seiyaku Co., Ltd. | Cyclic amp derivative ointments |
| WO1994002847A1 (en) * | 1992-07-27 | 1994-02-03 | Invitro International | In vitro test for dermal corrosive properties |
| US5411888A (en) * | 1992-07-27 | 1995-05-02 | Invitro International | In vitro test for dermal corrosive properties |
| US5612222A (en) * | 1992-07-27 | 1997-03-18 | In Vitro International | In vitro test for dermal corrosive properties |
| US5618274A (en) * | 1994-04-08 | 1997-04-08 | Rosenthal; Kenneth J. | Method and device for deep pressurized topical, fornix applied "nerve block" anesthesia |
| WO1998034653A1 (en) * | 1997-02-07 | 1998-08-13 | Queen's University At Kingston | Anaesthetic bone cement |
| US6713527B2 (en) * | 1997-02-07 | 2004-03-30 | Queen's University At Kingston | Anaesthetic bone cement |
| US20050027034A1 (en) * | 1997-02-07 | 2005-02-03 | Queen's University At Kingston | Anaesthetic bone cement |
| US6572580B2 (en) | 1998-08-06 | 2003-06-03 | Profoot, Inc. | Set depth nail notcher with patch system and method for treating nail fungus |
| US20030072724A1 (en) * | 1999-12-16 | 2003-04-17 | Maibach Howard I. | Topical pharmaceutical composition to treat hyperpigmentation of the skin |
| US20060002874A1 (en) * | 1999-12-16 | 2006-01-05 | Maibach Howard I | Topical pharmaceutical composition to treat hyperpigmentation of the skin |
| WO2001080814A1 (en) * | 2000-04-20 | 2001-11-01 | Profoot, Inc. | Set depth nail notcher with patch system and method for treating nail fungus |
| US7901716B2 (en) * | 2002-05-28 | 2011-03-08 | Md Bioalpha Co., Ltd. | Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| US20060034951A1 (en) * | 2002-05-28 | 2006-02-16 | Kwak Tae H | Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| US20040013744A1 (en) * | 2002-07-17 | 2004-01-22 | Goulbourne Mary J. | Ointment composition for treating decubitus ulcers and methods for its making and its use |
| US7655717B2 (en) | 2002-07-17 | 2010-02-02 | Mary J. Goulbourne | Ointment composition for treating decubitus ulcers and methods for its making and its use |
| US20040076671A1 (en) * | 2002-10-21 | 2004-04-22 | Aletha Tippett | Methods and compositions for topical wound treatment |
| US20070110797A1 (en) * | 2002-10-21 | 2007-05-17 | Aletha Tippett | Methods and Compositions For Topical Wound Treatment |
| US20050043253A1 (en) * | 2003-08-19 | 2005-02-24 | Cook Bradley R. | Use of wound healing compositions for prevention of infections and allergies |
| US20060040002A1 (en) * | 2004-08-17 | 2006-02-23 | Boitano Suzanne M | Anti-itch composition |
| US7976866B2 (en) | 2004-12-06 | 2011-07-12 | Opremcak E Mitchel | Bandage and method for vital bleaching of skin |
| US20060121100A1 (en) * | 2004-12-06 | 2006-06-08 | Opremcak E M | Bandage and method for vital bleaching of skin |
| EP2482807A2 (en) | 2009-10-02 | 2012-08-08 | The Brigham and Women's Hospital, Inc. | Compositions and methods of prophylaxis for contact dermatitis |
| EP2482807A4 (en) * | 2009-10-02 | 2013-04-24 | Brigham & Womens Hospital | COMPOSITIONS AND METHODS FOR PROPHYLAXIS FOR CONTACT ECZEMA |
| US20130011494A1 (en) * | 2011-07-10 | 2013-01-10 | Mohammad Rahimi | Composition for treating decubitus ulcers in diabetic and non-diabetic patients |
| RU2740453C2 (en) * | 2014-07-31 | 2021-01-14 | Аморфикал Лтд. | Non-aqueous liquid and semi-solid compositions of amorphous calcium carbonate |
| US11602542B2 (en) | 2014-07-31 | 2023-03-14 | Amorphical Ltd. | Non-aqueous liquid and semi-solid formulations of amorphous calcium carbonate |
| US20190060281A1 (en) * | 2017-08-24 | 2019-02-28 | Jessica S. WHITTLE | Compositions and treatment methods for diaper dermatitis and skin irritation |
| US20230346880A1 (en) * | 2022-02-25 | 2023-11-02 | University Of South Florida | Topical formulations for treatment of hypergranulation tissue |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4005191A (en) | Topical ointment composition | |
| US5529987A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| US4512978A (en) | Dermatological composition useful in the treatment of psoriasis | |
| US4604384A (en) | Pharmaceutical gel composition | |
| CA2627214C (en) | Topical pharmaceutical compositions comprising amino acids and sodium hyaluronate | |
| JP4526042B2 (en) | External preparation for wound treatment | |
| US6780439B2 (en) | Wound treatment solution and method for using same | |
| US4514384A (en) | Hemorrhoid treatment method | |
| US5550112A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| US20110077218A1 (en) | Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate | |
| WO1994015623A9 (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| US6730323B1 (en) | Microclysmic gel for treatment of tissue trauma and burns | |
| US3663716A (en) | Method of treating acne with benzyl alcohol | |
| JP3899267B2 (en) | Use of tosylchloramide to treat skin, mucous membrane, organ or tissue disorders | |
| EP1282429B1 (en) | Pharmaceutical gel composition | |
| DE102015222429A1 (en) | Biofilm forming agent for facilitating wound healing and covering and protecting biological organs | |
| RU2148397C1 (en) | Ointment for treatment of patient with dermatological sicknesses and skin damages | |
| US5498603A (en) | Method for the stimulation of hair growth | |
| RU2546030C1 (en) | Ichthyosin preparation | |
| AU558482B2 (en) | Pharmaceutical gel composition | |
| RU2545724C1 (en) | Method of treating trophic ulcers and persistent septic wounds | |
| UA144637U (en) | COMPOSITION FOR LOCAL TREATMENT OF FUNGAL DISEASES OF SKIN AND NAILS | |
| Wende | Ointments and Pastes: A Clinical Lecture Delivered at the Fitch Dispensary | |
| UA45810A (en) | LOCAL MEDICINE "TIM" FOR LOCAL APPLICATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCF | Information on status: patent grant |
Free format text: PATENTED FILE - (OLD CASE ADDED FOR FILE TRACKING PURPOSES) |